CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, Ph.D., to its Board of Directors, bringing decades of leadership and expertise in the biotech and healthcare industries. Concurrently, Fred Craves, Ph.D., will retire from the Board in July 2025 after more than 15 years of dedicated service.
Dr. Fouse is a seasoned executive with over 30 years of experience spanning healthcare, finance, and corporate strategy. She previously served as Chief Executive Officer of Agios Pharmaceuticals from 2019 to 2022 and continues to act as Chair of its Board. Her leadership background also includes executive roles at Celgene Corporation, where she was President and Chief Operating Officer, among other key positions. Prior to that, she held senior roles at Bunge Limited, Alcon Laboratories, and other international corporations. Her academic achievements include a Ph.D. in finance, in addition to advanced degrees in environmental management and wildlife forensics.
The addition of Dr. Fouse to Madrigal’s Board underscores the company’s commitment to advancing its strategic objectives, which include the continued launch of Rezdiffra, the first approved treatment for MASH, and ongoing development of its clinical programs for compensated MASH cirrhosis.
Dr. Craves, one of the founding figures of Madrigal, played a pivotal role in the company’s growth and success. His leadership over the years was instrumental in positioning Madrigal as a leader in MASH treatment innovation.
With this leadership transition, Madrigal is poised to continue its trajectory of growth and innovation in addressing unmet needs for patients with NASH and MASH, diseases that have historically lacked effective therapeutic solutions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.